Navigation Links
Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel
Date:6/30/2008

Company's End-of-Phase II Meeting with FDA Set for Sept. 29

LA JOLLA, Calif., June 30 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that data presented at the 50th Annual Scientific Meeting of the American Headache Society showed that, in addition to meeting the primary endpoint of headache pain relief at two hours, the company's lead AMPA/kainate-type glutamate receptor antagonist, tezampanel, demonstrated improvement on important secondary endpoints in a 306-patient Phase IIb clinical trial in acute migraine headache. Specifically, tezampanel demonstrated improvement in the following secondary endpoints: sustained headache response, absence of nausea or vomiting, absence of phonophobia and absence of photophobia.

"This is our second positive study in acute migraine with tezampanel," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines Therapeutics, who presented the data. "In both studies, we have shown improvement in all of the endpoints that the FDA has indicated will be required for the drug's approval. Earlier this year we conducted a clinical guidance call with the FDA in which the agency said it has no objection with us moving forward with a Phase III study of the 40 mg dose of tezampanel. We have scheduled an end-of-Phase II meeting to discuss the entire Phase III program with the agency on Sept. 29."

In the Phase IIb clinical trial, tezampanel was well tolerated with no reports of serious or medically important adverse events. At the 40 mg dose, the most commonly reported adverse events compared to placebo were injection site pain (5.1 percent vs. 20 percent), injection site burning (3.8 percent vs. 6.7 percent), dizziness (6.4 percent vs. 5.3 percen
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
2. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
3. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
4. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
5. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
6. Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting
7. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
8. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
9. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
10. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
11. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/s9qx9j/asia_pacific_open ) ... Open System MRI Market - Growth, Trends And ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... the fastest growing market for Open System MRI. ... replacing CT because of its higher sensitivity and ...
(Date:5/27/2015)... , May 27, 2015  With all the ... the services they provide to keep patients healthy should ... ripple effect of the Affordable Care Act continues to ... insurance payer partners, making it more important than ever ... communication with those they contract with for patient care. ...
(Date:5/27/2015)... , May 26, 2015 Research and Markets( ... "Asia Pacific Mammography Market - Growth, Trends And Forecasts ... Mammography is a detailed type of imaging ... A mammography exam, called a mammogram, is used to ... diseases in women. An x-ray (radiograph) is a noninvasive ...
Breaking Medicine Technology:Asia Pacific Open System MRI Market Trends and Forecasts 2015-2019 2Physicians Seek Payer Inclusion, Not Impediment 2Physicians Seek Payer Inclusion, Not Impediment 3Asia Pacific Mammography Market Trends and Forecasts 2015-2019 2
... Sept. 1, 2011 Hillcrest HealthCare System (HHS) ... Tulsa, Okla., and Claremore Regional Hospital in Claremore, Okla. ... not disclosed. The transaction included the assets ... Claremore Regional Hospital, more than 70 primary care physicians, ...
... 2011 ConvaTec Inc., a world-leading developer and marketer ... today announced that the company has acquired Boston Medical ... platform of specialized medical devices throughout Latin America. ... relationships in key Latin American markets, coupled with strong ...
Cached Medicine Technology:Hillcrest Completes Purchase of SouthCrest & Claremore Hospitals 2ConvaTec Announces Acquisition of Boston Medical Device 2
(Date:5/27/2015)... CURE® Magazine and the Bladder ... advance research, provide information and support, and raise awareness ... fifth most common type of cancer, which begins when ... out of control. , “CURE Magazine provides guidance ... the cancer experience through digital and print publications, live ...
(Date:5/27/2015)... ABILENE, Texas (PRWEB) May 27, 2015 ... addition of three FDA-approved dermal filler treatments in Abilene, ... designed to reduce the appearance of glabellar lines, better ... lines. Belotero Balance® is designed to treat smoker’s ... mouth to the chin, while Radiesse® improves the appearance ...
(Date:5/27/2015)... New York, NY (PRWEB) May 27, 2015 ... excellence, has launched in the U.S. with its first ... products are available for purchase nationwide through http://www.difassusa.com ... to a person’s health and productivity, but some people ... need each night. Dormiva™ is a sleep aid designed ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 Coco Libre announced ... be able to reach for Organic Coconut Water to quench ... will be available at VIP areas, artist greenrooms, corporate skyboxes ... available at area hotels and on festival shuttle buses. ... this year,” said Noa Elan, Director of Strategic Partnerships for ...
(Date:5/27/2015)... Cincinnati, Ohio (PRWEB) May 27, 2015 Cincinnati ... Education & Research for Veterans (CERV) Foundation is proud to ... information fair for women Veterans June 11 at the Freedom ... Reporter Karin Johnson will be the emcee. , This ... and devotion to the nation. The banquet is free ...
Breaking Medicine News(10 mins):Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 2Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 3Health News:The MedSpa at Hendrick Introduces Xeomin®, Belotero Balance® and Radiesse® Injectables 2Health News:Supplement Brand Difass USA Launches in the U.S. with Three Flagship Products Designed to Bring Balance Back to Your Life 2Health News:Coco Libre Puts Organic Coconut Water on the Line-up at BottleRock Napa 2Health News:Cincinnati VA Women’s Health Clinic Celebrates Women Veterans at Awards Banquet 2
... likely as the rest of the population to die an ... reveals research published ahead of print in the Journal of ... more than 1050 North American and European musicians and singers ... the musicians featured in the All Time Top 1000 albums, ...
... Acquisition of Consultech Strengthens Omnicom,s Presence in China,s Growing ... ... 3 Omnicom Group Inc.,("Omnicom") (NYSE: OMC ), the ... Diversified Agency Services,division ("DAS"), a majority ownership interest in Consultech, ...
... in Nashville, NASHVILLE, Tenn., Aug. 24 ... hold a press conference on,Tuesday, August 28 in ... Drug Administration (FDA) authority over tobacco products. The,leaders ... U.S. Representatives Bart Gordon (D-TN) and Marsha Blackburn,(R-TN) ...
... stomach may cause vitamin C to promote, rather than ... research published ahead of print in the journal Gut. ... fat (lipid) and vitamin C (ascorbic acid) on nitrite ... vulnerable to pre-cancerous changes and tumour growth. , ...
... ability to recover their heart rate variability following acute ... could increase their risk of coronary death, according to ... General Psychiatry, one of the JAMA/Archives journals. However, patients ... may experience more of an improvement in heart rate ...
... visits to a doctors office that resulted in a diagnosis ... 40 times over the last decade, reported researchers funded in ... same time period, the number of visits by adults resulting ... these increases is unclear. Medication prescription patterns for the two ...
Cached Medicine News:Health News:Pop stars more than twice as likely to die an early death 2Health News:Omnicom Acquires Leading Healthcare Marketing Communications Firm in China 2Health News:Omnicom Acquires Leading Healthcare Marketing Communications Firm in China 3Health News:Tennessee Faith Leaders Call on Reps. Gordon & Blackburn to Co-sponsor Legislation to Protect Kids from Tobacco 2Health News:Treating depression may improve recovery of heart rate variability following coronary syndromes 2Health News:Rates of bipolar diagnosis in youth rapidly climbing, treatment patterns similar to adults 2Health News:Rates of bipolar diagnosis in youth rapidly climbing, treatment patterns similar to adults 3Health News:Rates of bipolar diagnosis in youth rapidly climbing, treatment patterns similar to adults 4Health News:Rates of bipolar diagnosis in youth rapidly climbing, treatment patterns similar to adults 5
... Mumps IgG ELISA test system is intended ... antibody in human serum. When performed according ... test, together with other clinical information, may ... and/or aid in the diagnosis of Mumps ...
... IgG Enzyme-linked Immunosorbent Assay (ELISA) is intended ... IgG antibody to Mumps virus in human ... for the determination of immune status. Paired ... to demonstrate seroconversion or a significant rise ...
... the TEG analyzer and the TEG analytical software, ... formation and dissolution of the clot, showing the ... TEG analyzer is the only hemostasis analyzer available ... proven model developed by Prof. Helmut Hartert in ...
... BareWire technology, the wire crosses the lesion ... catheter. All other actions, including filter placement ... then occur over the wire., ,Emboshield is ... off during a carotid stenting procedure, and ...
Medicine Products: